Categories
Featured Juneau News Juneau Local Ketchikan Local News Feeds Sitka Local

Flu is rising rapidly, driven by a new variant. Here’s what to know

A certified medical assistant holds a syringe for a flu vaccine at a clinic in Seattle, on Wednesday, Sept. 10, 2025. (AP Photo/Lindsey Wasson, File)

AP-Flu is rising rapidly across the U.S., driven by a new variant of the virus — and cases are expected to keep growing with holiday travel.

That variant, known as “subclade K,” led to early outbreaks in the United Kingdom, Japan and Canada. In the U.S., flu typically begins its winter march in December. On Tuesday, the Centers for Disease Control and Prevention reported high or very high levels of illness in more than half the states.

The CDC estimated there have been at least 7.5 million illnesses, 81,000 hospitalizations and 3,100 deaths from flu so far this season. That includes at least eight child deaths — and is based on data as of Dec. 20, before major holiday gatherings.

Some states are particularly hard-hit. New York’s health department said the week ending Dec. 20 marked the most flu cases the state had recorded in a single week since 2004: 71,000.

It’s far too soon to know if this flu season will be as severe as last winter’s.

But it’s not too late to get a flu shot, which health experts say can still prevent severe illness even if someone gets infected. While this year’s vaccine isn’t a perfect match to the subclade K strain, a preliminary analysis from the U.K. found it offered at least partial protection, lowering people’s risk of hospitalization.

According to the CDC, only about 42% of adults and children have gotten a flu vaccination so far this year.

What is subclade K flu?

The flu virus is a shape-shifter, constantly mutating, and it comes in multiple forms. There are two subtypes of Type A flu, and subclade K is a mutated version of one of them, named H3N2. That H3N2 strain is always harsh, especially for older adults.

Subclade K’s mutations aren’t enough of a change to be considered an entirely new kind of flu.

But they’re different enough to evade some of the protection from this year’s vaccine, said Andrew Pekosz, a virus expert at Johns Hopkins Bloomberg School of Public Health.

Will subclade K make people sicker?

The CDC said it’s too soon to know how severe this season will be.

Flu seasons dominated by any version of H3N2 tend to be bad, with more infections overall and more people becoming seriously ill. But Hopkins’ Pekosz cautioned it will take time to tease apart whether this subclade K version simply spreads more easily or also is more dangerous.

That question aside, the CDC notes there are some prescription medicines to treat flu — usually recommended for people at high risk of complications. But they generally need to be started a day or two after symptoms begin.

Who needs a flu vaccine?

The CDC and major medical societies all recommend a flu vaccine for just about everyone age 6 months and older. Despite lots of recent misinformation and confusion about vaccines, the flu recommendations haven’t changed.

Flu is particularly dangerous for people 65 and older, pregnant women, young children and people of any age who have chronic health problems, including asthma, diabetes, heart disease and weak immune systems.

The vaccines are brewed to protect against three influenza strains. Despite concern over that new H3N2 variant, they appear to be a good match against H1N1 and Type B flu that may also circulate this year, Pekosz said.

There are shots for all ages, as well as the nasal spray FluMist for ages 2 to 49. For the first time this year, some people may be eligible to vaccinate themselves with FluMist at home.

Categories
Featured Juneau News Juneau Local Ketchikan Local News Feeds Sitka Local

RFK Jr. pulls $500 million in funding for vaccine development

Protesters hold signs and chant outside the Alaska Native Tribal Health Consortium where U.S. Health Secretary Robert F. Kennedy Jr. met with Alaska Native leaders, in Anchorage, Alaska, Tuesday, Aug. 5, 2025, shortly after the Department of Health and Human Services announced its plans to cancel contracts and pull funding for some vaccines being developed to fight respiratory viruses like COVID-19 and the flu. (AP Photo/Mark Thiessen)

AP- The Department of Health and Human Services will cancel contracts and pull funding for some vaccines that are being developed to fight respiratory viruses like COVID-19 and the flu.

Robert F. Kennedy Jr. announced in a statement Tuesday that 22 projects, totaling $500 million, to develop vaccines using mRNA technology will be halted.

Kennedy’s decision to terminate the projects is the latest in a string of decisions that have put the longtime vaccine critic’s doubts about shots into full effect at the nation’s health department. Kennedy has pulled back recommendations around the COVID-19 shots, fired the panel that makes vaccine recommendations, and refused to offer a vigorous endorsement of vaccinations as a measles outbreak worsened.

The health secretary criticized mRNA vaccines in a video on his social media accounts, explaining the decision to cancel projects being led by the nation’s leading pharmaceutical companies, including Pfizer and Moderna, that offer protection against viruses like the flu, COVID-19 and H5N1.

“To replace the troubled mRNA programs, we’re prioritizing the development of safer, broader vaccine strategies, like whole-virus vaccines and novel platforms that don’t collapse when viruses mutate,” Kennedy said in the video.

Infectious disease experts say the mRNA technology used in vaccines is safe, and they credit its development during the first Trump administration with slowing the 2020 coronavirus pandemic. Future pandemics, they warned, will be harder to stop without the help of mRNA.

“I don’t think I’ve seen a more dangerous decision in public health in my 50 years in the business,” said Mike Osterholm, a University of Minnesota expert on infectious diseases and pandemic preparations.

He noted mRNA technology offers potential advantages of rapid production, crucial in the event of a new pandemic that requires a new vaccine.

The shelving of the mRNA projects is short-sighted as concerns about a bird flu pandemic continue to loom, said Dr. Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia.

“It’s certainly saved millions of lives,” Offit said of the existing mRNA vaccines.

Scientists are using mRNA for more than infectious disease vaccines, with researchers around the world exploring its use for cancer immunotherapies. At the White House earlier this year, billionaire tech entrepreneur Larry Ellison praised mRNA for its potential to treat cancer.

Traditionally, vaccines have required growing pieces of viruses, often in chicken eggs or giant vats of cells, then purifying that material. The mRNA approach starts with a snippet of genetic code that carries instructions for making proteins. Scientists pick the protein to target, inject that blueprint and the body makes just enough to trigger immune protection — producing its own vaccine dose.

In a statement Tuesday, HHS said “other uses of mRNA technology within the department are not impacted by this announcement.”

The mRNA technology is used in approved COVID-19 and RSV shots, but has not yet been approved for a flu shot. Moderna, which was studying a combination COVID-19 and flu mRNA shot, had said it believed mRNA could speed up production of flu shots compared with traditional vaccines.

The abandoned mRNA projects signal a “shift in vaccine development priorities,” the health department said in its statement, adding that it will start “investing in better solutions.”

“Let me be absolutely clear, HHS supports safe, effective vaccines for every American who wants them,” Kennedy said in the statement.

Speaking hours later Tuesday at a news conference in Anchorage, Alaska, alongside the state’s two Republican U.S. senators, Kennedy said work is underway on an alternative.

He said a “universal vaccine” that mimics “natural immunity” is the administration’s focus.

“It could be effective — we believe it’s going to be effective — against not only coronaviruses, but also flu,” he said.